GlassScriptPhysician profile
Henry J Vanpala
NPI 1710241658
$40,402.03
in general payments reported to CMS, 2019-2025
82 companies · $4,990 in 2025
The $4,990 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,794 · 2020: $3,329 · 2021: $6,661 · 2022: $8,278 · 2023: $6,233 · 2024: $6,118 · 2025: $4,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,061.94 |
| Education | $278.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,607.65 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $4,550.66 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $3,708.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,690.27 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Lilly USA, LLC | $1,605.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,388.83 | 2020-2025 | Caplyta |
| Allergan, INC. | $1,280.83 | 2019-2020 | |
| Axsome Therapeutics, INC. | $1,032.83 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $984.11 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $954.42 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Amarin Pharma, INC. | $945.94 | 2019-2023 | |
| Pfizer INC. | $901.45 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $713.24 | 2019-2022 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $672.64 | 2019-2025 | Trintellix, Glassia, Gattex |
| Teva Pharmaceuticals USA, INC. | $588.83 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Vanpala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.